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The South African national HIV prevalence among antenatal women 
aged 15 - 49 years in the 2008 antenatal care (ANC) survey was 29.3% 
(95% confidence interval (CI) 28.5 - 30.1%), and 16.1% (CI 12.6 - 
20.2%) in the Western Cape, which is the least burdened province.¹ 
From 2006 to 2007, 67.5% of HIV-positive women in the Western 
Cape received at least a single dose of nevirapine during labour.²
All HIV-positive pregnant women who meet South African 
national treatment guidelines may be referred to antiretroviral 
treatment clinics for antiretroviral therapy (ART) as per World 
Health Organization (WHO) guidelines.³ South Africa follows 2002 
WHO guidelines with stage IV disease or a CD4 cell count of 200 
cells/µl as a threshold for starting ART.
Perinatal transmission risk increases with low CD4 counts and 
high viral loads in the mother.4-6 Large cohort studies in the developed 
world have shown ART to be superior to AZT monotherapy,7,8 and 
the WHO recommends that all pregnant women with stage III or 
IV disease, or  a CD4 cell count <350 cells/µl, should receive ART.9,10 
While HIV transmission rates range from 0 - 2.9% for women in the 
developed world,7,8,11-13 the efficacy of ART in preventing vertical 
transmission has not been clearly documented in resource-limited 
settings. A study of 326 women in Côte d’Ivoire showed improved 
prevention of ART v. prevention of mother-to-child transmission 
therapy (PMTCT) (2.3% v. 16.1%, p<0.0001; where PMTCT was 
either AZT from 36 weeks or AZT and lamivudine from 32 weeks, 
with intrapartum nevirapine and 1 week’s AZT for the infant).14 
Transmission rates from a hospital-based combined antenatal and 
antiretroviral clinic in Johannesburg were 5% for 689 patients on 
ART.15 Since these data come from small research cohorts, more 
programmatic data on ART initiation in pregnancy are needed.
We studied the uptake of ART and rates and risk factors for vertical 
HIV transmission among pregnant women referred for ART at a large 
community ART clinic, and the characteristics of mothers receiving 
ART compared with PMTCT or no intervention.
Methods
The ART service was based at the Gugulethu Community 
Health Centre in Nyanga, Cape Town.16 This peri-urban 
area is home to a predominantly black population of over 
300 000, most of whom live in low socio-economic conditions. In 
2005, the antenatal HIV seroprevalence was 29%.17 By September 
2008, 3 407 patients had been started on ART at this clinic according 
to national guidelines, except that the commencement CD4 cell 
count threshold was extended from <200 cells/µl to <250 cells/µl for 
pregnant women in January 2006. Pregnant women were referred for 
ART from an onsite ANC service 130 m away.18
The ART service has regular laboratory monitoring and adherence 
support from community-based peer counsellors.16 Enrolment of 
pregnant patients was stratified by gestational age so that women 
<24 weeks pregnant would follow the standard protocol of ART 
commencement within 4 weeks; women between 24 and 34 weeks 
were fast-tracked to initiate therapy in 2 weeks; and those >34 weeks 
pregnant were aimed to start within a week. Drugs for fast-tracked 
patients were ordered on the day of their first attendance, and they 
were escorted to meet the counsellor team leader by their doctor. 
They could commence treatment even if they had not yet attended 
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Objective. To examine the uptake of ART among pregnant women 
referred to an ART service and the associated rates and risk factors 
for vertical HIV transmission.
Method. Retrospective analysis of an observational cohort at a 
community ART clinic in Cape Town.
Results. Between 2002 and 2008, 367 treatment-naïve pregnant 
women accessed the clinic. The median age was 27.5 years, and 
median gestation at presentation was 28 weeks. The median baseline 
CD4 count and viral load were 134 cells/µl and 28 282 copies/ml. 
Two hundred and sixty-five women (72%) commenced ART 
before giving birth, 73 women (20%) were referred for prevention 
of mother-to-child transmission therapy (PMTCT), and 29 (8%) 
received no intervention. Among ART-eligible women, 13% were 
lost to follow-up. Of those starting ART, median duration of therapy 
prior to birth was 7.6 weeks (interquartile range (IQR) 4 - 11.9).The 
HIV transmission rate was 5.1% (95% confidence interval (CI) 2.8 - 
9.0%). Factors associated with transmission were advanced maternal 
WHO disease stage (odds ratio (OR) 9.57, p=0.02), and follow-up 
viral load above 50 copies/ml (OR 3.64, p=0.03). Each additional 
week on ART reduced transmission by 20% (p=0.05). There was 
no HIV transmission among women who received more than 8 
weeks’ therapy.
Conclusions. The rate of HIV transmission in this study was 
higher than reported in high-income countries. Prevention of 
vertical transmission with ART was hindered by women presenting 
late in pregnancy and with advanced stage of HIV disease. 
Interventions that facilitate earlier ART commencement and 
improve programmatic retention of pregnant women are required.
S Afr Med J 2010; 100: 827-831. 
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all 3 education sessions, although these had to be attended in due 
course.
Patients referred after 28 weeks were started on AZT monotherapy 
at the ANC service while awaiting ART. Zidovudine, lamivudine 
and nevirapine was the regimen of choice for pregnant women 
unless contraindicated, in which case an alternative regimen was 
constructed. ART-naïve women accessing the service between 1 
September 2002 and 1 March 2008 were eligible for analysis if they 
were pregnant at first attendance. Singleton and multiple pregnancies 
were evaluable.
Women started on triple therapy before birth were categorised as 
the ‘ART’ group; women referred back to a maternity outpatient unit 
for PMTCT and not commenced on ART were categorised as the 
‘PMTCT’ group; and women not started on ART prior to birth with 
no documented referral for PMTCT or having received AZT prior to 
birth were categorised as the ‘No intervention’ group.
Demographic data, WHO staging, treatment outcomes, laboratory 
results, ART regimens and regimen changes were recorded in a 
prospectively maintained database for all patients referred to the 
ART service since the start of the clinic in September 2002. Infant 
HIV status and age at polymerase chain reaction (PCR) testing were 
verified using the regional laboratory PCR test database. National 
guidelines are that PCR testing should take place at 6 weeks of age.³ 
Infant HIV status was followed up until September 2008.
Data analysis was by STATA/IC version 10. Fisher’s exact tests 
and Wilcoxon rank-sum tests were used to compare proportions 
and medians, respectively. Multiple logistic regression was used to 
examine the odds of vertical transmission according to maternal 
clinical characteristics. The upper bound of the rate of transmission 
was calculated according to Ghent working group formulae.19 For 
calculating the upper bound, only first-born twins were included as 
per the formula. For other calculations, both twins were included. All 
women provided informed consent. Data collection from this clinic 
for the study was approved by the University of Cape Town Research 
Ethics Committee.
Results
Maternal characteristics
Between 2002 and 2008, 2 350 ART-naïve women were referred for 
ART, and 367 were identified as pregnant at first clinic attendance. 
Their median age was 27.5 years (range 15 - 44); median gestational 
age 28 weeks (interquartile range (IQR) 24 - 32), and the median 
baseline CD4 cell count and viral load were 134/µl (IQR 88 - 179) and 
28 282 copies/ml (IQR 8 103 - 74 859) respectively.
Intervention received
Two hundred and sixty-five mothers (73%) started ART prior to 
giving birth; 73 (20%) were referred back from the ART clinic 
to the midwife obstetric unit (MOU) for PMTCT, and 29 (8%) 
had no intervention (Fig. 1). After exclusion of 6 women who 
were confirmed to be ineligible for ART, 13 refused ART and 7 
started ART later. Altogether, 44 out of 346 (12.7%, 95% CI 9.6 - 
16.7%) eligible women were lost to follow-up or refused ART and 
therefore were not started on ART.
Women who commenced ART started a median of 21 days after 
enrolment (IQR 14 - 29); the median period on ART before birth 
was 7.6 weeks (IQR 4 - 11.9) (Fig. 2). The choice of ART regimen 
depended on maternal condition. Two hundred and forty-six (93%) 
started AZT, 3TC and NVP; 12 (5%) commenced d4T, 3TC and NVP 
owing to anaemia; 6 (2%) started d4T 3TC and EFV owing to TB 
and advanced pregnancy; and 1 (0.3%) started d4T 3TC and Kaletra. 
There were 8 regimen changes during pregnancy.
Comparison of PMTCT, ART and No 
Intervention Received
The demographics and outcomes of the groups of ART and PMTCT 
were compared (Table I). The PMTCT group were more advanced 
in their pregnancy, and had higher baseline CD4 cell counts and 
lower baseline viral loads (p<0.001, p<0.001, p=0.013 respectively). 
There was no difference in distribution of live births and stillbirths, 
or in HIV status of infants. The groups that received no intervention 
were significantly younger than those started on ART (p=0.02), 
and were more likely to have TB (p=0.015) and to have stillbirths 
(p=0.004). Both groups gave birth at earlier gestational age than the 
ART group.
Maternal and pregnancy outcomes
Of the women commenced on ART, 16 (6%) were lost to the 
programme prior to giving birth. Of these, 9 (3%) were lost to follow-
up, 5 (2%) died and 2 were transferred to another ART clinic. Of the 
5 deaths, 3 were due to TB and 1 to pneumonia, and the cause of the 
fifth was unknown. Overall, 34 (9.3%) pregnant women had TB.
Fig. 2. Timeline of ART initiation in women commencing therapy from con-
ception until first follow-up viral load test after delivery using median values 
of days.
-196 21 53 62
-200 -150 -100 -50 0 50 100 150
Time in days
Fig. 1. Flowchart of interventions received by pregnant women accessing 
ART clinic, and infant outcomes of those commencing ART.
 
ART naive women aged 
13-59 enrolled  (N=2350)
Pregnant women including 9  
twin pairs (N=367 mothers, 
376 pregnancies)
Women referred back for 
PMTCT (N=73 mothers, 74 
pregnancies)
31 (42%) refused ART 
16(22%) high CD4    
21(28%) started later  
5(8%) transfer/other
Women started on ART 
before birth 
(N=265 mothers
273 pregnanices)
Live births (N=241)
HiV negative (N=206) HIV positive (N=11) Status unknown (N=24)
Miscarriage/Stillbirth (N=15)
Termination (N=4)
Unknown Outcome (N=13)
No intervention before birth 
(N=29)
13 (45%) refused ART  
6(21%) high CD4 
7(24%)started later 
1 (3%) died           
2(7%)transfer 
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There were 376 pregnancies among the 367 women including 9 sets 
of twins. There were 279 live births (74%), 21 stillbirths/miscarriages 
(6%), 4 terminations (1%) and 72 (19%) were of unknown outcome. 
Median estimated gestational age at birth or stillbirth was 38 weeks 
(IQR 36 - 40). There were 232 HIV-negative infants (83%), 11 HIV-
positive (4%), and 36 (13%) infants of unknown HIV status. Median 
infant age at PCR was 13 weeks (IQR 10 - 17).
Twenty-one (5.6%) pregnancies ended in either stillbirth or 
miscarriage, 2 at 19 weeks’ gestation, 18 between 28 and 42 weeks, and 
1 unrecorded. Stillbirths and miscarriages were analysed together. In 
multivariate analysis, longer duration of pregnancy at enrolment (OR 
0.88, p=0.001) and commencing ART v. no intervention (OR 0.1, 
p=0.007) were protective. Higher baseline log viral load increased the 
risk (OR 2.46, p=0.07).
Nine infants died within 1 year of birth; the median age at death 
was 14 weeks (IQR 6 - 26). Three were HIV-positive, 2 negative and 
4 unknown. Maternal TB was associated with infant death in crude 
analysis (p=0.042) but, in multivariate analysis, only HIV-positive 
status was independently associated with infant death (OR 30.5, 
p=0.001).
Risk factors for vertical transmission
The groups of HIV-negative, positive and status-unknown infants 
born to women commenced on ART were compared (Table II). 
There were 241 births in this group. Median age at PCR was 13 weeks 
(IQR 10 - 17). Two hundred and six infants were negative (85%), 11 
(4.6%) positive, and 24 (10%) of unknown status (Fig. 1). Four of the 
infants of unknown HIV status died under the age of 17 weeks, and 
the remaining mothers of 20 infants had been transferred to another 
clinic, were lost to follow-up, or the infant had not been tested. The 
mother of infants of unknown status were younger (p=0.018).
After exclusion of unknowns, the transmission rate was 5.1% (95% 
CI 2.8 - 9.0%). The upper bound for the rate of transmission within 
the ART group estimated by the Ghent working group formulae was 
7.83% (95% CI 4.9 - 12.2).19
Crude analysis showed duration of ART before birth to be 
significantly associated with transmission (p=0.029). All of the 
mothers who gave birth to HIV-positive infants had less than 8 weeks’ 
ART prior to delivery. Advanced maternal disease stage (stage III or 
IV compared with I or II, p=0.01), gestation at enrolment (p=0.036) 
and first follow-up viral load >50 copies/ml (p=0.018) were also 
significantly associated. No significant difference was found in HIV 
status of infant according to maternal ART regimen.
Multivariate analysis of the HIV-positive versus negative infants 
revealed duration of ART to be an independent predictor of 
transmission (Table III). Each week reduced risk of transmission 
by 20% (p=0.005). Additional independent predictor variables were 
maternal WHO stage at enrolment and viral load at first follow-up. 
Table I. Maternal characteristics stratified by intervention received* 
Maternal characteristics 
and pregnancy outcomes
ART
(N=273)
PMTCT
(N=74)
p-value ART v. 
PMTCT
No intervention
(N=29)
p-value ART v. no 
intervention
Age 27.8 (25 - 31) 27 (23 - 32) 0.547 24.5 (23.5 - 28.5) 0.02
WHO stage I and II
III
IV
Unknown
179 (79%)
78 (34%)
8 (3%)
0
55 (74%)
16 (23%)
2 (3%)
0
0.146
15 (52%)
13 (45%)
0
1 (3%)
0.296
TB at enrolment 23 (8%) 5 (7%) 0.425 7 (24%) 0.015
Gestation at enrolment 27 (22 - 31) 32 (29 - 34) <0.001 26 (22-30) 0.878
CD4 at baseline 127 (84 - 168)
(N=268)
166 (128 - 267)
(N=67)
<0.001 153 (75 - 247)
(N=24)
0.109
Viral load at baseline 30 721 (2 762 - 50 545)
(N=267)
17 794 (2 762 - 50 545)
(N=67)
0.013
40 812 (14 969 - 91 870)
(N=24)
0.262
Gestation at birth 38.3 (36 - 40)
(N=252)
36 (34 - 38)
(N=30)
0.002 34 (27 - 39)
(N=8)
0.028
Live birth
Stillbirth/miscarriage
Termination/abortion
Unknown
241 (88%)
14 (5%)
4 (2%)
14 (5%)
31 (42%)
2 (3%)
0
41 (55%)
<0.001 (live v. 
stillbirth, p=0.568)
7 (24%)
4 (14%)
0
18 (62%)
<0.001 (live 
v. stillbirths, 
p=0.004)
Of live births:  
HIV-negative
HIV-positive
HIV status unknown
203 (84%)
11 (5%)
27 (11%)
23 (74%)
0
8 (26%)
0.067 (excluding 
unknowns, 
p=0.317)
3 (43%)
0
4 (57%)
0.011 (excluding 
unknowns, 
p=0.855)
VL<400 at first follow-up
400<10 000
>10 000
Unknown
Days after start
203 (74%)
10 (4%)
20 (7%)
40 (15%)
115 (112 - 124)
CD4 at first follow-up
Days after start
257 (165 - 335)
(N=233)
115 (112 - 124)
*For continuous variables, data represent medians (interquartile range).
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Women with WHO stage 3 or 4 disease were 9.5 times more likely 
to transmit (p=0.02) than those at stage 1. Those with incompletely 
suppressed virus (viral load >50 copies/ml) at 16 weeks on ART had 
a transmission rate of 10% (95% CI 4 - 20%), whereas those with a 
viral load of <50 copies/ml had a transmission rate of 3% (95% CI 
1 - 8%).
Discussion
The HIV transmission rate of those starting HAART during pregnancy 
was 5.1%, with an upper bound of 7.8% that was higher than rates 
reported in the developed world.7,8,11 Our study demonstrated that 
shorter duration of HAART in pregnancy was strongly associated with 
increased HIV transmission. The major factor limiting the potential 
duration of ART was advanced gestation at the time of presentation 
to the antenatal services. The period of ART was further shortened 
by systems delays in referral from the antenatal to the ART service 
severely restricting the time available to prepare women for ART.
The median gestational age at enrolment was 28 weeks. However, 
25% of patients presented after 31 weeks of pregnancy. The potential 
duration of ART was further restricted because delivery tended to 
occur early at a median of 38 weeks with 25% of mothers giving 
birth before 36 weeks’ gestation. This limited window of opportunity 
for ART initiation resulted in a strategy of fast-tracking of women 
presenting in the third trimester of pregnancy. Fast-tracking may not 
be an optimal strategy but was considered necessary as an emergency 
intervention precipitated by late booking. Women accessing ART 
programmes during pregnancy are significantly more likely to be 
lost to follow-up than their non-pregnant peers.20,21 The reasons 
behind poor retention of pregnant women within ART programmes 
are uncertain; however, too little preparation prior to ART initiation 
could be a contributing factor.
Lack of treatment readiness was also an important constraint to 
implementation as 21% of eligible women either refused or delayed 
commencement of ART to after delivery. Such women had already 
Table II. Table of maternal characteristics stratified by HIV status of infant*
Maternal characteristics 
and pregnancy 
outcomes
HIV-negative infants
(N=206)
HIV-positive infants
(N=11)
p-value HIV-negative 
v. HIV-positive
Infants unknown HIV 
status
(N=24)
p-value HIV-
negative v. 
unknown
Age 28.2 (25 - 32) 26.5 (22 - 30) 0.138 24 (25 - 28) 0.018
WHO stage I and II
III
IV
145 (70%)
55 (27%)
6 (3%)
3 (27%)
6 (55%)
2 (18%)
0.01 23 (85%)
4 (15%)
0
0.637
TB at enrolment 15 (7%) 2 (18%) 0.214 1 (4%) 0.416
Gestation at enrolment 27 (23 - 31)
(N=205)
32 (28 - 34)
(N=11)
0.036 27 (23 - 31)
(N=24)
0.835
CD4 at baseline 125 (81 - 164)
(N=202)
174 (118 - 193)
(N=11)
0.063 144 (78 - 186)
(N=23)
0.18
VL at baseline 29 537 (8 969 - 75 758)
(N=199)
32 086 (14 409 - 67 656)
(N=11)
0.746 13 250 (1 800 - 40 176)
(N=23)
0.024
Weeks on ART 
(median)
7.6 (4 - 12) 4.7 (2.7 - 7.6) 0.029 8 (5 - 12) 0.684
Gestation at birth 38 (36 - 40)
(N=201)
40 (37 - 41)
(N=11)
0.33 39 (38 - 41)
(N=13)
0.241
Delivery mode: NVD
Caesarean
Unknown
68 (33%)
54 (26%)
85 (41%)
2 (27%)
3 (18%)
6 (55%)
0.43
9 (37%)
6 (6%)
10 (41%)
0.488
First follow-up viral 
load
Start to follow-up VL 
(days)
<50 (0)
(N=192)
115 (112 - 123)
54 (49 - 791)
(N=11)
129 (112 - 158)
0.018
0.777
49 (0)
(N=15)
112 (112 - 116)
0.387
0.271
<400 at first follow-up
400<10 000
>10 000
Unknown
169 (82%)
7 (3%)
16 (8%)
11 (5%)
8 (73%)
1 (9%)
2 (18%)
0
0.235
14 (58%)
0
1 (4%)
10 (42%)
1
CD4 at first follow-up
Start to follow-up CD4 
(days)
248 (162 - 327)
(N=196)
115 (112 - 123)
337 (182 - 455)
(N=11)
119 (111 - 194)
0.207
0.584
247 (160 - 299)
(N=15)
112 (112 - 116)
0.869
0.384
Breastfeeding
Not breastfeeding
6 (3%)
122 (58%)
0
7 (64%)
0.722 1 (4%)
6 (26%)
0.312
Median age at PCR 
(days)
93 (75 - 124)
(N=122)
87 (70 - 93)
(N=7)
*For continuous variables, data represent medians (interquartile range).
831
ORIGINAL ARTICLES
December 2010, Vol. 100, No. 12  SAMJ
successfully navigated their way through antenatal booking and 
referral before attending the ART clinic. As losses may occur at earlier 
stages of the entire cascade of antenatal clinic attendance, counselling 
and testing, referral for treatment, initiation of HAART and ongoing 
adherence to protocol, true losses from the programme are likely to 
have been even greater.
In the developed world, vertical HIV transmission rates of between 0% 
and 2.9% have been achieved for women on HAART.8,11-13 Triple therapy 
(HAART) is superior to AZT monotherapy in preventing mother-
to-child transmission.7,8 Similarly, in this study, there were no HIV 
transmissions among women who received at least 8 weeks of therapy 
before delivery. The overall HIV transmission rate among our patients 
highlights that the effectiveness of HAART for vertical transmission is 
affected by the potency of the regimen used and also by other operational 
constraints. One contributing factor is that the present national ART 
treatment guidelines restrict HAART to those with AIDS or CD4 <200 
cells/µl. Pregnant black women with high viral loads require several 
weeks of therapy to completely suppress viral load.¹²
Our data highlight that the effectiveness of HAART will be greatly 
increased if women can be encouraged to access antenatal services 
at an earlier stage of gestation. Antenatal services should also place 
emphasis on retaining women within care.
There were few adverse events related to use of HAART but there 
were multiple sequelae of untreated HIV. However, a significant 
proportion of women refused or delayed initiation of HAART. Social 
marketing of the benefits of HAART is urgently required to overcome 
the negative messages previously propagated by South Africa’s 
health authorities. The limited window of opportunity for initiating 
HAART in women presenting later in pregnancy has required fast-
tracking them. Whether inadequate preparation due to fast-tracking 
plays a part in the poor retention of pregnant women in HAART 
programmes must be investigated.
We studied the effectiveness of HAART and did not address 
important parameters such as mode of delivery, breastfeeding and 
infant post-exposure prophylaxis. Additionally, pregnancy outcomes 
of the women referred back for PMTCT were unknown. Direct 
comparison of the effectiveness of PMTCT v. HAART in this study 
was therefore not possible. Interpreting the analysis of live v. stillbirths 
is complex, as women having miscarriages or early stillbirths would 
not attend the antenatal clinic, which builds in an ascertainment 
bias. Similarly, longer duration of pregnancy at enrolment emerged 
as protective, but this may have been because the more advanced the 
pregnancy, the less time there is for a stillbirth to occur.
The generalisability of the data to other parts of South Africa and 
the rest of sub-Saharan Africa is difficult to establish. This is one 
unique programme, and other public sector services may initiate 
ART more slowly. In other areas, antenatal booking may be later still, 
and treatment initiation may be further slowed by delays in CD4 
enumeration. Further programmatic data are needed.
Summary
The rate of vertical HIV transmission (5.1%) among women 
commencing ART in this cohort was higher than that reported 
in the developed world, and was associated with advanced 
immunodeficiency at presentation and late initiation of HAART. 
No HIV transmissions occurred among women who received more 
than 8 weeks of HAART. However, 12.7% of women eligible for ART 
during pregnancy did not receive it and, in those starting HAART, the 
median length of therapy before delivery was less than 8 weeks. The 
effectiveness of HAART will be improved by earlier presentation to 
antenatal services and subsequent retention in care. Increased uptake 
of HAART will require social marketing of the considerable benefits 
of HAART in this patient population.
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